Do analysts rate CURX or SKYE?

Skye Bioscience has a consensus target price of $8.50, suggesting a potential upside of 1,270.75%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger valuation & earnings, CURX or SKYE?

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is CURX or SKYE more profitable?

Curanex Pharmaceuticals' return on equity of -85.41% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -85.41% -82.11% Skye Bioscience N/A -217.27% -162.39%

Do analysts rate CURX or NCEL?

NLS Pharmaceutics has a consensus price target of $23.00, indicating a potential upside of 477.89%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, analysts clearly believe NLS Pharmaceutics is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, CURX or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is CURX or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -85.41% -82.11% NLS Pharmaceutics N/A N/A N/A

Do analysts prefer AYTU or CURX?

Aytu BioPharma presently has a consensus target price of $10.75, suggesting a potential upside of 388.64%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, research analysts plainly believe Aytu BioPharma is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend CURX or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, CURX or ALVR?

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is CURX or ALVR more profitable?

AlloVir's return on equity of -71.03% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -85.41% -82.11% AlloVir N/A -71.03% -61.27%

Do analysts rate MDCX or CURX?

Medicus Pharma currently has a consensus price target of $9.00, indicating a potential upside of 2,373.89%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, MDCX or CURX?

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicus Pharma N/A N/A -$35.46M -$2.68 N/A Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A

Is MDCX or CURX more profitable?

Curanex Pharmaceuticals' return on equity of -85.41% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -311.33% Curanex Pharmaceuticals N/A -85.41% -82.11%

Curanex Pharmaceuticals (CURX) Competitors

$0.21 0.00 (-0.43%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$0.21 +0.00 (+0.48%)

As of 04:07 AM Eastern

Compare

CURX vs. SKYE, NCEL, AYTU, ALVR, and MDCX

Should you buy Curanex Pharmaceuticals stock or one of its competitors? MarketBeat compares Curanex Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Curanex Pharmaceuticals include Skye Bioscience (SKYE), NLS Pharmaceutics (NCEL), Aytu BioPharma (AYTU), AlloVir (ALVR), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry.

How does Curanex Pharmaceuticals compare to Skye Bioscience?

Curanex Pharmaceuticals (NASDAQ:CURX) and Skye Bioscience (NASDAQ:SKYE) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Curanex Pharmaceuticals' return on equity of -85.41% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%
Skye Bioscience	N/A	-217.27%	-162.39%

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

21.1% of Skye Bioscience shares are held by institutional investors. 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Comparatively, 6.2% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Skye Bioscience has a consensus target price of $8.50, suggesting a potential upside of 1,270.75%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Skye Bioscience had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 3 mentions for Skye Bioscience and 2 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.44 beat Skye Bioscience's score of 0.47 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Positive
Skye Bioscience	Neutral

Summary

Skye Bioscience beats Curanex Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to NLS Pharmaceutics?

Curanex Pharmaceuticals (NASDAQ:CURX) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

NLS Pharmaceutics has a consensus price target of $23.00, indicating a potential upside of 477.89%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, analysts clearly believe NLS Pharmaceutics is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NLS Pharmaceutics' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%
NLS Pharmaceutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

In the previous week, NLS Pharmaceutics had 2 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 4 mentions for NLS Pharmaceutics and 2 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.44 beat NLS Pharmaceutics' score of 0.72 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Positive
NLS Pharmaceutics	Positive

Summary

NLS Pharmaceutics beats Curanex Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Curanex Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.36	-$13.56M	-$4.58	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

In the previous week, Curanex Pharmaceuticals had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 2 mentions for Curanex Pharmaceuticals and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 1.87 beat Curanex Pharmaceuticals' score of 1.44 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Aytu BioPharma	Very Positive
Curanex Pharmaceuticals	Positive

33.5% of Aytu BioPharma shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aytu BioPharma presently has a consensus target price of $10.75, suggesting a potential upside of 388.64%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, research analysts plainly believe Aytu BioPharma is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curanex Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

Summary

Aytu BioPharma beats Curanex Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to AlloVir?

Curanex Pharmaceuticals (NASDAQ:CURX) and AlloVir (NASDAQ:ALVR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

66.1% of AlloVir shares are owned by institutional investors. 39.7% of Curanex Pharmaceuticals shares are owned by company insiders. Comparatively, 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Curanex Pharmaceuticals had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for Curanex Pharmaceuticals and 0 mentions for AlloVir. Curanex Pharmaceuticals' average media sentiment score of 1.44 beat AlloVir's score of 0.00 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Positive
AlloVir	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AlloVir's return on equity of -71.03% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%
AlloVir	N/A	-71.03%	-61.27%

Summary

Curanex Pharmaceuticals beats AlloVir on 6 of the 10 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Medicus Pharma currently has a consensus price target of $9.00, indicating a potential upside of 2,373.89%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

In the previous week, Medicus Pharma and Medicus Pharma both had 2 articles in the media. Curanex Pharmaceuticals' average media sentiment score of 1.44 beat Medicus Pharma's score of 1.43 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Medicus Pharma	Positive
Curanex Pharmaceuticals	Positive

Curanex Pharmaceuticals' return on equity of -85.41% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

Summary

Curanex Pharmaceuticals beats Medicus Pharma on 5 of the 9 factors compared between the two stocks.

Get Curanex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CURX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CURX vs. The Competition

Export

Metric	Curanex Pharmaceuticals	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$5.98M	$755.77M	$4.39B	$12.44B
Dividend Yield	N/A	4.84%	30.61%	8.42%
P/E Ratio	-0.78	1.54	23.66	24.38
Price / Sales	N/A	115.05	147.54	91.92
Price / Cash	N/A	20.06	165.47	59.36
Price / Book	0.53	8.57	12.86	6.33
Net Income	-$4.22M	-$3.66M	$118.20M	$331.02M
7 Day Performance	-0.10%	-2.87%	-0.83%	-0.33%
1 Month Performance	-37.78%	-1.90%	-2.89%	-1.29%
1 Year Performance	N/A	35.53%	11.37%	21.30%

Curanex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CURX Curanex Pharmaceuticals	1.0611 of 5 stars	$0.21 -0.4%	N/A	N/A	$5.98M	N/A	N/A	N/A	Positive News Short Interest Decrease
SKYE Skye Bioscience	2.1437 of 5 stars	$0.70 -0.9%	$8.50 +1,119.5%	-84.2%	$24.49M	N/A	N/A	11
NCEL NLS Pharmaceutics	3.6112 of 5 stars	$4.48 +5.9%	N/A	-81.3%	$23.97M	N/A	N/A	6	Analyst Forecast Gap Up
AYTU Aytu BioPharma	2.7467 of 5 stars	$2.22 +1.8%	$10.75 +384.2%	+2.3%	$23.82M	$66.38M	N/A	160
ALVR AlloVir	N/A	$4.71 -2.5%	N/A	+81.9%	$23.75M	N/A	N/A	110	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CURX) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. SKYE, NCEL, AYTU, ALVR, and MDCX

How does Curanex Pharmaceuticals compare to Skye Bioscience?

Summary

How does Curanex Pharmaceuticals compare to NLS Pharmaceutics?

Summary

How does Curanex Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Curanex Pharmaceuticals compare to AlloVir?

Summary

How does Curanex Pharmaceuticals compare to Medicus Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. SKYE, NCEL, AYTU, ALVR, and MDCX

How does Curanex Pharmaceuticals compare to Skye Bioscience?

Is CURX or SKYE more profitable?

Which has stronger valuation & earnings, CURX or SKYE?

Do insiders and institutionals hold more shares of CURX or SKYE?

Do analysts rate CURX or SKYE?

Does the media favor CURX or SKYE?

Summary

How does Curanex Pharmaceuticals compare to NLS Pharmaceutics?

Do analysts rate CURX or NCEL?

Is CURX or NCEL more profitable?

Which has stronger earnings and valuation, CURX or NCEL?

Does the media prefer CURX or NCEL?

Summary

How does Curanex Pharmaceuticals compare to Aytu BioPharma?

Which has better earnings & valuation, AYTU or CURX?

Does the media favor AYTU or CURX?

Do institutionals and insiders hold more shares of AYTU or CURX?

Do analysts prefer AYTU or CURX?

Is AYTU or CURX more profitable?

Summary

How does Curanex Pharmaceuticals compare to AlloVir?

Which has stronger earnings & valuation, CURX or ALVR?

Do insiders & institutionals hold more shares of CURX or ALVR?

Does the media prefer CURX or ALVR?

Do analysts recommend CURX or ALVR?

Is CURX or ALVR more profitable?

Summary

How does Curanex Pharmaceuticals compare to Medicus Pharma?

Do analysts rate MDCX or CURX?

Which has preferable earnings & valuation, MDCX or CURX?

Does the media prefer MDCX or CURX?

Is MDCX or CURX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools